The LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial was a pivotal milestone as it showed the cardiovascular benefits of liraglutide in patients with T2D and high cardiovascular risk
Acute injuries typically respond faster than chronic degenerative conditions
Sanjaykumar Patel Sanjaykumar Patel Published Dec 27, 2025 In the high-stakes pharmaceutical industry, building a "blockbuster" is rare, but maintaining its dominance for decades is nearly impossible
Weight Loss Most diets and weight loss programs focus solely on eating habits, but thats only half of the equation
The U.S Food and Drug Administration initially rejected it after it appeared to cause several types of tumors in rats, but when a one-year human trial showed no apparent cancer, it was approved, and went on to become one of the most frequently prescribed weight-loss drugs
Tea Tree and Aloe keep everything calm